AI Terminal
DIACEUTICS PLC
Regulatory Filings • Aug 4, 2023
7596_rns_2023-08-04_6adf3fc6-6ee9-41c9-9dc8-351c4e60165b.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2666I
Diaceutics PLC
04 August 2023
04 August 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Diaceutics to present at Canaccord Genuity 43rd Annual Growth Conference in Boston
Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, today announces that management will attend and present at the Canaccord Genuity 43rd Annual Growth Conference taking place on August 7-10 in Boston, MA.
The Conference brings together investors from around the world with some of the best and most promising growth companies in Canaccord's core sectors - Technology, Healthcare, Digital & Tech-Enabled Health, Sustainability, Industrials, and Consumer & Retail. For more information please click here.
Enquiries:
| Diaceutics PLC | Tel: +44 (0)28 9040 6500 |
| Peter Keeling, Chief Executive Officer Ryan Keeling, Chief Innovation Officer Nick Roberts, Chief Financial Officer |
[email protected] |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland Kate Hanshaw |
|
| Alma PR | Tel: +44 (0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Matthew Young | |
| Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by our proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRANKNBQQBKDFFK